TN2013000178A1 - Moyens et methodes de traitement du lymphomeb diffus a grandes cellules - Google Patents

Moyens et methodes de traitement du lymphomeb diffus a grandes cellules

Info

Publication number
TN2013000178A1
TN2013000178A1 TNP2013000178A TN2013000178A TN2013000178A1 TN 2013000178 A1 TN2013000178 A1 TN 2013000178A1 TN P2013000178 A TNP2013000178 A TN P2013000178A TN 2013000178 A TN2013000178 A TN 2013000178A TN 2013000178 A1 TN2013000178 A1 TN 2013000178A1
Authority
TN
Tunisia
Prior art keywords
lymphoma
methods
treatment
cell
large cell
Prior art date
Application number
TNP2013000178A
Other languages
English (en)
Inventor
Gerhard Zugmaier
Dirk Nagorsen
Juergen Scheele
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/068851 external-priority patent/WO2012055961A1/fr
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of TN2013000178A1 publication Critical patent/TN2013000178A1/fr

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des moyens et des méthodes de traitement du lymphome B diffus à grandes cellules (DLBCL). L'invention concerne en particulier l'administration d'un anticorps CDI 9 x CD3 bispécifique activant des lymphocytes T par l'intermédiaire de sa partie de liaison au CD3 et se liant de façon concomitante au CD! 9, notamment sur la surface des cellules du lymphome, par l'intermédiaire de sa partie de liaison au CD 19 (à savoir un activateur de lymphocytes T bispécifique, "Bi TE"), dans le traitement d'une masse tumorale de tissu lymphoréticulaire et/ou d'un lymphome extranodal causé par le DLBCL chez un patient.
TNP2013000178A 2011-10-27 2013-04-24 Moyens et methodes de traitement du lymphomeb diffus a grandes cellules TN2013000178A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2011/068851 WO2012055961A1 (fr) 2010-10-27 2011-10-27 Moyens et méthodes de traitement du lymphome b diffus à grandes cellules

Publications (1)

Publication Number Publication Date
TN2013000178A1 true TN2013000178A1 (fr) 2014-11-10

Family

ID=54360613

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000178A TN2013000178A1 (fr) 2011-10-27 2013-04-24 Moyens et methodes de traitement du lymphomeb diffus a grandes cellules

Country Status (1)

Country Link
TN (1) TN2013000178A1 (fr)

Similar Documents

Publication Publication Date Title
MA34619B1 (fr) Moyens et méthodes de traitement du lymphome b diffus à grandes cellules
Poggi et al. How to hit mesenchymal stromal cells and make the tumor microenvironment immunostimulant rather than immunosuppressive
Li et al. Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy
Porichis et al. Immune checkpoint blockade restores HIV-specific CD4 T cell help for NK cells
Desancé et al. Chondrogenic differentiation of defined equine mesenchymal stem cells derived from umbilical cord blood for use in cartilage repair therapy
Wang et al. mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE 2
Allan et al. CD1d and CD1c expression in human B cells is regulated by activation and retinoic acid receptor signaling
Castella et al. Immunotherapy: a novel era of promising treatments for multiple myeloma
Lisowska et al. Hemodialysis affects phenotype and proliferation of CD4-positive T lymphocytes
McKay et al. Kidney transplantation and the ageing immune system
de Haart et al. Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
BRPI0512017A (pt) dosagem otimizada com anticorpos anti-cd4 para indução de toleráncia em primatas
MA35800B1 (fr) Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
EA201070463A1 (ru) Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство
Gras Navarro et al. Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival
Chen et al. A critical role for the retinoic acid signaling pathway in the pathophysiology of gastrointestinal graft-versus-host disease
Yu et al. RP105 engages phosphatidylinositol 3-kinase p110δ to facilitate the trafficking and secretion of cytokines in macrophages during mycobacterial infection
Chen et al. γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation
Liao et al. Aged hematopoietic stem cells entrap regulatory T cells to create a prosurvival microenvironment
Bekić et al. Mesenchymal stromal cells from healthy and Inflamed Human Gingiva Respond differently to Porphyromonas gingivalis
Smith et al. B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity
Glebezdina et al. Molecular mechanisms of control of differentiation of regulatory T-lymphocytes by exogenous melatonin
Vorontsova et al. The dichotomous role of bone marrow derived cells in the chemotherapy-treated tumor microenvironment